Tokyo Tape
Sign in
← Kawaguchi Chemical Industry

Quarterly report · Q3

4361.TEDINET S100PAIT
Period2021-12-01 → 2022-08-31
Filed2022-10-11
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥6.1bn2021-12-01 → 2022-08-31Cons.Net sales
Revenue¥7.9bn2020-12-01 → 2021-11-30Cons.Net sales (5-year summary)
Revenue¥5.8bn2020-12-01 → 2021-08-31Cons.Net sales
Operating income¥331m2021-12-01 → 2022-08-31Cons.Operating income
Operating income¥347m2020-12-01 → 2021-08-31Cons.Operating income
Ordinary income¥345m2021-12-01 → 2022-08-31Cons.Ordinary income
Ordinary income¥386m2020-12-01 → 2021-11-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥349m2020-12-01 → 2021-08-31Cons.Ordinary income
Profit before tax¥343m2021-12-01 → 2022-08-31Cons.Income before income taxes
Profit before tax¥357m2020-12-01 → 2021-08-31Cons.Income before income taxes
Net income (owners)¥266m2021-12-01 → 2022-08-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥281m2020-12-01 → 2021-11-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥259m2020-12-01 → 2021-08-31Cons.Profit loss attributable to owners of parent
Net income¥266m2021-12-01 → 2022-08-31Cons.Profit loss
Net income¥259m2020-12-01 → 2021-08-31Cons.Profit loss
Total assets¥8.3bnat 2022-08-31Cons.Assets
Total assets¥7.9bnat 2021-11-30Cons.Assets
Total assets¥7.7bnat 2021-08-31Cons.Total assets (5-year summary)
Total liabilities¥5.9bnat 2022-08-31Cons.Liabilities
Total liabilities¥5.6bnat 2021-11-30Cons.Liabilities
Net assets / equity¥2.5bnat 2022-08-31Cons.Net assets
Net assets / equity¥2.3bnat 2021-11-30Cons.Net assets
Net assets / equity¥2.2bnat 2021-08-31Cons.Net assets (5-year summary)
Cash and deposits¥1.1bnat 2022-08-31Cons.Cash and deposits
Cash and deposits¥1.3bnat 2021-11-30Cons.Cash and deposits
EPS (basic)¥218.072021-12-01 → 2022-08-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥71.012022-06-01 → 2022-08-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥230.992020-12-01 → 2021-11-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥213.082020-12-01 → 2021-08-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥52.782021-06-01 → 2021-08-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio29.6%at 2022-08-31Cons.Equity to asset ratio (5-year summary)
Equity ratio28.5%at 2021-11-30Cons.Equity to asset ratio (5-year summary)
Equity ratio28.8%at 2021-08-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 18
SegmentItemPeriodValue
jpcrp040300-q3r_E01006-000Pharmaceutical Productsreportable segmentrevenue2021-12-01 → 2022-08-31¥6.1bn
jpcrp040300-q3r_E01006-000Pharmaceutical Productsreportable segmentrevenue external2021-12-01 → 2022-08-31¥6.1bn
jpcrp040300-q3r_E01006-000Pharmaceutical Productsreportable segmentsegment profit2021-12-01 → 2022-08-31¥308m
jpcrp040300-q3r_E01006-000Real Estate Leasingreportable segmentrevenue2021-12-01 → 2022-08-31¥29m
jpcrp040300-q3r_E01006-000Real Estate Leasingreportable segmentrevenue external2021-12-01 → 2022-08-31¥29m
jpcrp040300-q3r_E01006-000Real Estate Leasingreportable segmentsegment profit2021-12-01 → 2022-08-31¥23m
Total Of Reportable Segments And Otherssegment totalrevenue2021-12-01 → 2022-08-31¥6.1bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-12-01 → 2022-08-31¥6.1bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-12-01 → 2022-08-31¥331m
jpcrp040300-q3r_E01006-000Pharmaceutical Productsreportable segmentrevenue2020-12-01 → 2021-08-31¥5.7bn
jpcrp040300-q3r_E01006-000Pharmaceutical Productsreportable segmentrevenue external2020-12-01 → 2021-08-31¥5.7bn
jpcrp040300-q3r_E01006-000Pharmaceutical Productsreportable segmentsegment profit2020-12-01 → 2021-08-31¥324m
jpcrp040300-q3r_E01006-000Real Estate Leasingreportable segmentrevenue2020-12-01 → 2021-08-31¥28m
jpcrp040300-q3r_E01006-000Real Estate Leasingreportable segmentrevenue external2020-12-01 → 2021-08-31¥28m
jpcrp040300-q3r_E01006-000Real Estate Leasingreportable segmentsegment profit2020-12-01 → 2021-08-31¥23m
Total Of Reportable Segments And Otherssegment totalrevenue2020-12-01 → 2021-08-31¥5.8bn
Total Of Reportable Segments And Otherssegment totalrevenue external2020-12-01 → 2021-08-31¥5.8bn
Total Of Reportable Segments And Otherssegment totalsegment profit2020-12-01 → 2021-08-31¥347m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 352
ItemContextValueUnit
Profit loss attributable to non controlling interestsPrior1YTDDuration－JPY
Profit loss attributable to non controlling interestsCurrentYTDDuration－JPY
Profit loss attributable to owners of parentPrior1YTDDuration259487000JPY
Profit loss attributable to owners of parentCurrentYTDDuration265514000JPY
Profit lossPrior1YTDDuration259487000JPY
Profit lossCurrentYTDDuration265514000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration20418000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration-13168000JPY
Foreign currency translation adjustment net of tax ociPrior1YTDDuration8620000JPY
Foreign currency translation adjustment net of tax ociCurrentYTDDuration22346000JPY
Other comprehensive incomePrior1YTDDuration29039000JPY
Other comprehensive incomeCurrentYTDDuration9178000JPY
Comprehensive incomePrior1YTDDuration288527000JPY
Comprehensive incomeCurrentYTDDuration274692000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration288527000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration274692000JPY
Comprehensive income attributable to non controlling interestsPrior1YTDDuration－JPY
Comprehensive income attributable to non controlling interestsCurrentYTDDuration－JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E01006-000PharmaceuticalProductsReportableSegmentsMember5735248000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E01006-000RealEstateLeasingReportableSegmentMember28493000JPY
Revenues from external customersPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember5763742000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration5763742000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E01006-000PharmaceuticalProductsReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E01006-000RealEstateLeasingReportableSegmentMember－JPY
Transactions with other segmentsPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember－JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember－JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E01006-000PharmaceuticalProductsReportableSegmentsMember5735248000JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E01006-000RealEstateLeasingReportableSegmentMember28493000JPY
Net salesPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember5763742000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember－JPY
Net salesPrior1YTDDuration5763742000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E01006-000PharmaceuticalProductsReportableSegmentsMember323853000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E01006-000RealEstateLeasingReportableSegmentMember22787000JPY
Operating incomePrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember346641000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember－JPY
Operating incomePrior1YTDDuration346641000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E01006-000PharmaceuticalProductsReportableSegmentsMember6057641000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E01006-000RealEstateLeasingReportableSegmentMember28502000JPY
Revenues from external customersCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember6086144000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration6086144000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q3r_E01006-000PharmaceuticalProductsReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q3r_E01006-000RealEstateLeasingReportableSegmentMember－JPY
Transactions with other segmentsCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember－JPY
Transactions with other segmentsCurrentYTDDuration_ReconcilingItemsMember－JPY
Transactions with other segmentsCurrentYTDDuration－JPY
Net salesCurrentYTDDuration_jpcrp040300-q3r_E01006-000PharmaceuticalProductsReportableSegmentsMember6057641000JPY
Net salesCurrentYTDDuration_jpcrp040300-q3r_E01006-000RealEstateLeasingReportableSegmentMember28502000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2021-11-30pass
balance sheet identityconsolidated 2022-08-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2021-11-30pass
statement vs summary · net assetsconsolidated 2022-08-31pass
statement vs summary · net income attributable to parentconsolidated 2020-12-01/2021-08-31pass
statement vs summary · net income attributable to parentconsolidated 2021-12-01/2022-08-31pass
statement vs summary · revenueconsolidated 2020-12-01/2021-08-31pass
statement vs summary · revenueconsolidated 2021-12-01/2022-08-31pass
statement vs summary · total assetsconsolidated 2021-11-30pass
statement vs summary · total assetsconsolidated 2022-08-31pass